PharmaDeals Review: Latest Articles

All the latest analysis of deal-making activity in the pharmaceutical and biotechnology sector provided by the experts from the PharmaDeals Review.

103 results.

Pages - 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10 - 11

  • Published on: 2008-07-21 Roche Seizes its Chance to Buy Genentech Roche offering to buy the remaining 44% of Genentech for US$43.7 B could dramatically change the biotechnology landscape in the US. The question is will it create a new drugs powerhouse or just fizzle out as another in a long series of takeovers.
  • Published on: 2008-07-18 Teva Strengthens its Position in the US and Spanish Markets Teva has entered into one of its biggest deals with the acquisition of US generics giant, Barr Pharmaceuticals, and completed the purchase of Bentley Pharmaceuticals in Spain - substantially increasing its product portfolio both in the US and European markets.
  • Published on: 2008-07-14 No More Sleepless Nights For Actelion? Actelion signed a major deal with GlaxoSmithKline to develop and commercialise the sleep medication, almorexant. The deal could be worth up to CHF 3.3 B (US$3.25 B) to Actelion if specific milestones and sales targets in insomnia and two additional indications are met.
  • Published on: 2008-07-10 Novartis Takes Back Tekturna Novartis purchased an additional 51.7% stake in Speedel Holding Ltd. The two companies jointly developed the high blood pressure drug, Tekturna (aliskiren), which was approved in Europe and the US in 2007.
  • Published on: 2008-07-10 Access Pharmaceuticals Boosts Product Pipeline Through Acquisition of MacroChem Access Pharmaceuticals is to gain a number of late-stage anticancer and dermatological products through its acquisition of specialty pharmaceutical company MacroChem. The anticancer products are synergistic to Access oncology portfolio but the dermatology products are expected to be out-licensed.
  • Published on: 2008-07-07 Fresenius in Risky Deal-making Fresenius has recently become involved in a number of areas which may concern investors – namely the heparin controversy and the ‘non-approvable’ product Injectafer®. However, closer inspection can explain the company’s recent deal-making.
  • Published on: 2008-07-03 Pfizer’s Global Strategy Begins in Asia Pfizer entered into two deals in Asia which suggest that developments are taking shape following a global re-evaluation of the business. Pfizer China is partnering with NovaMed to promote oncology products and Pfizer’s global restructuring results in the spinning off of its Japanese research lab.
  • Published on: 2008-07-03 Shire Acquisition Provides Company with a Market-Ready Drug Shire adds yet another rare disease-targeting drug to its portfolio with its acquisition of Berlin-based Jerini.
  • Published on: 2008-07-02 Altea and Hospira Form a Transdermal Patch Partnership Altea Therapeutics entered into an agreement with Hospira for the development and commercialisation of an undisclosed product utilizing Altea’s proprietary PassPort Transdermal Delivery System. For Altea, the deal could be worth up to $109 M in development and sales performance milestone payments.
  • Published on: 2008-06-18 Roche Gains Novel Anticancer Antibody Product Roche has entered into a deal for TB-403, a novel anticancer agent jointly developed by BioInvent International and ThromboGenics. The angiogenesis inhibitor has many advantages over current treatments and could make a significant impact on the cancer market.

103 results.

Pages - 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10 - 11

Bookmarks

Bookmark PharmaDeals through one of these social networks.